Post-Coronavirus Warnings From EU Pharma Industry
Need To Ensure IP & Manufacturing Relaxations Are Temporary
Executive Summary
Speakers at a recent COVID-19 webinar discussed a number of issues related to the pandemic, including intellectual property protections, matching supply with demand, and what to do about excess manufacturing capacity once the crisis is over.